Cellular therapy: >= 42 days after the completion of any type of cellular therapy (e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.)
Absolute granulocytes >= 1500 cells/uL (1.5 x 10^9 L)
Inadequate hematologic function (unless due to underlying lymphoma), defined as follows: Hemoglobin less than (<) 9 grams per decilitre (g/dL), absolute neutrophil count (ANC) <1.5*10^9 cells per liter (cells/L), platelet count <75*10^9 cells/L
Platelet count > 50,000 cells/dL (50 x 10e9/L)
Platelet count >= 50,000 cells/mm^3 (50 x 10^9/L) at least 3 weeks prior to screening unless attributable to disease; platelet count >= 20,000 cells/mm^3 is permissible if due to disease
Platelet count > 75,000 cells/mm^3 (75 x 10^9/L), if thrombocytopenia is due to bone marrow involvement platelet count must be >= 50,000 cells/mm^3
RETREATMENT WITH MODIFIED T-CELLS INCLUSION CRITERIA: Subject has < 5 % detectable modified T cells in peripheral blood (can be done at any time prior)
Platelet count ? 75,000 cells/mm3 (75 x 109/L) (without required transfusions during the 10 days prior to initiation of therapy)
Platelets >= 50,000 cells/mm^3 for patients who have bone marrow plasmacytosis < 50% or >= 30,000 cells/mm^3 for patients who have bone marrow plasmacytosis of >= 50%, obtained =< 14 days prior to registration
Platelet count >= 75,000 cells/mm^3 (75 x 10^9/L) must be met during screening (within 21 days) and also prior to study drug administration on cycle 1 day 1
Platelet counts of >= 100,000 cells/mm^3 for patients who have bone marrow plasmacytosis of < 50%, or platelets >= 50,000 cells/mm^3 for patients who have bone marrow plasmacytosis of >= 50%
Platelet >= 30,000 cells/mm^3
Participants with platelet level >= 50,000/mm^3, within 21 days of initiation of protocol therapy for patients in whom < 50% of bone marrow nucleated cells are plasma cells; or platelet count >= 30,000/mm^3 for participants in whom > 50% of bone marrow nucleated cells are plasma cells; transfusion within 7 days of screening is not allowed to meet platelet eligibility criteria
Participants with platelet level < 50,000/mm^3, within 21 days of initiation of protocol therapy for patients in whom < 50% of bone marrow nucleated cells are plasma cells; or platelet count < 30,000/mm^3 for participants in whom > 50% of bone marrow nucleated cells are plasma cells; transfusion within 7 days of screening is not allowed to meet platelet eligibility criteria
Platelet count >/=50,000 cells/mcL, or >/=30,000 cells/mcL if more than 50% bone marrow involvement (Cohorts A, B, D, E, F)
Obtained =< 14 days prior to registration: Plasmacytosis < 50% or >= 30,000 cells/mm^3 for patients who have bone marrow plasmacytosis of >= 50%
Bone marrow plasma cells < 10% or > 60%
Unable to generate antigen-specific WT1-specific CD8+ T cells for infusions; however, if a lower than planned number of cells is available, the patient will have the option to receive the generated WT1-specific T cells
Successful test expansion -cells
Platelet count >= 70,000 cells/mm^3 if marrow plasmacytosis < 50%; platelet count >= 30,000 cells/mm^3 if marrow plasmacytosis >= 50%
Platelet count >= 50,000/?l (>= 30,000/?l if bone marrow plasma cells are >= 50% of cellularity)
RETREATMENT WITH MODIFIED T CELLS: Subject has < 5% detectable modified T cells in peripheral blood (can be done any time prior)
Platelet count >= 100,000 cells/mm^3 or >= 100 bil/L
Platelet >= 75,000 cells/mm^3
Platelet count >= 100,000 cells/mm^3 or >= 100 bil/L
Patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count (AGC) of >/= 1500 cells/mm3 and platelet count of >/= 100,000 cells/mm3;
Cellular therapy: ?42 days after the completion of any type of cellular therapy (eg, modified T-cells, natural killer cells, dendritic cells, etc)
ANC < 1000 cells/mm3 or < 750 cells/mm3 due to >50% marrow involvement
Hematology: ANC >1500 cells/mm3, platelet count >100,000 cells/mm3 and Hemoglobin > 9 gm/L
Platelets >= 50,000 cells/mm^3 if marrow plasmacytosis < 50% OR platelet count >= 30,000 cells/mm^3 if marrow plasmacytosis >= 50%
Less than 5% plasma cells in the peripheral blood leukocytes
Platelets >= 50,000 cells/mm^3 for patients who have bone marrow plasmacytosis < 50% or >= 30,000 cells/mm^3 for patients who have bone marrow plasmacytosis of >= 50% within 14 days prior to registration
Aggregates or sheets of one of the following: lymphocytes, plasma cells or\n                  lymphoplasmacytic cells on the bone marrow biopsy (measured within 28 days prior\n                  to registration).
Participants with platelet level < 50,000/mm^3, within 21 days of initiation of protocol therapy for patients in whom < 50% of bone marrow nucleated cells are plasma cells; or platelet count < 30,000/mm^3 for patients in whom >= 50% of bone marrow nucleated cells are plasma cells; transfusion within 7 days of screening is not allowed to meet platelet eligibility criteria
Platelet count < 50,000/mm^3 within 21 days of initiation of protocol therapy for patients in whom < 50% of bone marrow nucleated cells are plasma cells; or platelet count < 30,000/mm^3 for patients in whom >= 50% of bone marrow nucleated cells are plasma cells; transfusion is not allowed to meet platelet eligibility criteria
Platelet count ? 50,000 cells/?L, or ? 30,000 cells/?L in subjects with documented bone marrow involvement, and without transfusion support 7 days before assessment. Subjects with transfusion-dependent thrombocytopenia are excluded.
For RCC, platelet count ?80,000 cells/mm3
For urothelial carcinoma, gastric or GEJ adenocarcinoma, and CRC, platelet count ?100,000 cells/mm3
Phase 2 subjects with known lymphoma: >= 50,000 cells/mm3; >=25,000 cells/mm3 for subjects with lymphoma in bone marrow
Untransfused platelet count < 75,000 cells/?L
Platelet count ? 75 X 109/L (in patients with < 50% of bone marrow nucleated cells were plasma cells) or ? 50 X 109/L (in patients with ? 50% of bone marrow nucleated cells were plasma cells) without transfusion or growth factor support
Platelet count ? 75,000 cells/dL (75 x 109/L)
Within 14 days prior to registration: Platelet count >= 70,000 cells/mm^3 for patients who have bone marrow plasmacytosis < 50%; or >= 50,000 cells/mm^3 for patients who have bone marrow plasmacytosis of >= 50%
Platelets (plt) ? 75 x 109/L in subjects in whom < 50% of bone marrow mononuclear cells are plasma cells or ? 30 x 109/L in subjects in whom ? 50% of bone marrow mononuclear cells are plasma cells.
Platelets inferior to 75 000 cells per µL if inferior to 50% of bone marrow (BM) nucleated cells are plasma cells, and inferior to 30 000 cells per µL if superior or equal to 50% of BM nucleated cells are plasma cells. Platelet transfusion is not allowed within three days before the screening visit.
Adequate baseline CBC, renal and hepatic function. Parameters described as WBC>3000 cells/mm^3, ANC>1,000 cells/mm^3, hemoglobin>9.5g/dL, and platelet count >100,000 cells/mm^3
Participant has adequate hematological functions [absolute neutrophil count (ANC) ? 1500 cells/microliter (mcL), hemoglobin ? 9 grams/deciliter (g/dL), and platelets ? 100,000 cells/mcL and ? 850,000 cells/mcL]
Neutropenia ? 800 cells/µl
Unable to generate antigen-specific WT1-specific CD8+ T cells for infusions; however, the patient will have the option to receive WT1-specific T-cells if a lower than planned number of cells is available
Patients with plasma cells > 50% of bone marrow nucleated cells, and platelets >= 30,000/uL will be permitted regardless of the baseline ANC, if it is felt to be related to active myeloma and if in the opinion of the investigator, growth factor support can result in improvement in the neutrophil count to greater than 1000/uL (including during screening period)
Platelet count >= 75,000/uL for patients in whom < 50% of bone marrow nucleated cells are plasma cells; or a platelet count >= 50,000/uL for patients in whom >= 50% of bone marrow nucleated cells are plasma cells; platelet transfusions are not allowed within 3 days of last platelet assessment to confirm eligibility
Platelet count < 75,000/ µL for patients in whom < 50% of bone marrow nucleated cells are plasma cells; and < 50,000/ µL for patients in whom ? 50% of bone marrow nucleated cells are plasma cells
Platelet count > 75,000 cells/mm^3 (75 x 10^9/L), if thrombocytopenia is due to bone marrow involvement platelet count must be 50,000 cells/mm^3
Cellular Therapy: ?42 days after the completion of any type of cellular therapy (eg, modified T cells, natural killer cells, dendritic cells, etc)
Platelet count >= 100,000 cells/mm^3 or >= 100 bil/L
Platelet count < 30 x 10^9/L, unless myeloma-related; if MM-related (hypercellular marrow biopsy of > 80% and packed with at least 80% plasma cells) the enrolling investigator must document this
Platelet count >= 100,000 cells/mm^3 or >= 100 bil/L
Platelet count >= 100,000 cells/mm^3 or >= 100 bil/L
Successful test expansion of T-cells
Within one week of study entry: Platelet count at least 100,000 cells/mm^3
Lab criteria of absolute neutrophil count (ANC) >/= 1000 cells/mm3, platelets >/= 80,000 cells/mm3 if baseline bone marrow negative for TCL involvement and platelets >/= 20,000 cells/mm3 if baseline bone marrow positive for TCL involvement, bilirubin </= 2 x upper limits of normal (ULN) (Gilbert's </= 3 x ULN), creatinine </= 1.5 x ULN, and ALT and AST </= 3 x ULN.
Platelets >= 75 x 10^9/L; if the bone marrow contains >= 50% plasma cells, a platelet count of >= 50 x 10^9/L is allowed
Patients must meet the following laboratory criteria within 28 days of starting therapy: * Absolute neutrophil count (ANC) >/= 1.0 x 10^9/L * Hemoglobin >/= 8 g/dl ( transfusion are permitted) * Platelet count > 70,000 cells/mm^3 for patients with < 50% of bone marrow plasma cells or platelet count > 25,000 cells/mm^3 for patients in whom > 50% of the bone marrow nucleated cells were plasma cells * aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) </= 2.5 x ULN * Serum bilirubin </= 2 x ULN
Adequate hematologic status ANC >=1,500cells/mm3 Platelet Count >= 100,000cells/mm3 Hemoglobin >=9.0g/dL
Adequate hematologic status ANC >=1,500cells/mm3 Platelet Count >=100,000cells/mm3 Hemoglobin >=9.0g/dL
DONOR: Donors who are not expected to meet the minimum target dose of marrow cells (1 x 10^8 nucleated cells/kg recipient ideal body weight [IBW]) for the initial HCT; the average nucleated cell content of harvested marrow is 22 x 10^6 nucleated cells/mL or 220 x 10^8 nucleated cells/Liter
Platelet count >= 100 x 10^9 cells/L
Adequate bone marrow function (hemoglobin ? 9.0 g/dL; platelets ? 75 x10^9 cells/L; absolute neutrophil count ? 1.0x10^9 cells/L).
Adequate bone marrow function (hemoglobin ?9.0 g/dL; platelets ?100 x10^9 cells/L; absolute neutrophil count ?1.5x10^9 cells/L) without the use of hematopoietic growth factors.
Platelet count > 50,000 cells/dL (50 x 109/L)
Platelet count ? 100,000 cells/mm3 (100 x 109/L) or ? 50,000 cells/mm3 (50 x 109/L) if secondary to bone marrow involvement by disease.
Platelets ? 100,000 cells/?L (with no evidence that this platelet count was induced or supported by a platelet-stimulating agent)
Hematology: ANC >1500 cells/mm3, platelet count > 150,000 cells/mm3 and Hemoglobin > 9 g/dL
Platelet count > 50,000 cells/mm^3 for patients with < 50% of bone marrow plasma cells OR platelet count > 25,000 cells/mm^3 for patients in whom > 50% of the bone marrow nucleated cells were plasma cells
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L for patients in whom < 50% of bone marrow nucleated cells are plasma cells; or an ANC > 1.0 x 10^9/L for patients in whom > 50% of bone marrow nucleated cells are plasma cells; ANC must be independent of granulocyte colony-stimulating factor (G-CSF) for >= 1 week and pegylated G-CSF for >= 2 weeks prior to screening
Platelets >= 100 x 10^9/L for patients in whom < 50% of bone marrow nucleated cells are plasma cells; or > 75 x 10^9/L for patients in whom > 50% of bone marrow nucleated cells are plasma cells; screening platelet count independent of platelet transfusions for at least 2 weeks
Platelet count of ? 75x109/L in patients in whom <50% of bone marrow nucleated cells are plasma cells and ?50x109/L in patients in whom more than 50% of bone marrow nucleated cells are plasma cells.
Platelet count < 75,000/ ?L for subjects in whom < 50% of bone marrow nucleated cells are plasma cells
Untransfused platelet count < 50,000 cells/µL (50 x 10^9/L)
Required prior to infusion of ATLCAR.CD30 cells: Platelet count >= 25,000 cells/mm^3 without transfusion over preceding 5 days
Ki-67 >= 2% positivity (>= 500 cells)
Cohort 2 -Positive expression is defined as ?1+ by immunohistochemistry in ?1% cells, but not to exceed 2+ and/or 3+ in ? 50% of cells.
FNA results positive for cancer cells
